North America Digital Therapeutic (DTx) Market – Industry Trends and Forecast to 2028

Market Analysis and Insights: North America Digital Therapeutic (DTx) Market

The digital therapeutic (DTx) market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 23.4% in the forecast period of 2021 to 2028 and is expected to reach USD 10,639.36 million by 2028. Increasing prevalence of chronic diseases such as diabetes, hypertension among others as well as the rising awareness by government agencies will increase the growth of the digital therapeutic (DTx) market.

Digital therapeutics (DTx) deliver therapeutic interventions directly to patients using employing evidence-based, remote assessed software to serve, manage and avert a broad spectrum of behavioural, mental and physical disorders. They are utilized alone or mix with medications, devices or other therapies to optimize patient care and health outcomes. Rising remote access to therapies that are clinically tested as safe and effective is one of the properties of digital therapeutics (DTx) during the treatment.

The technological advancement which the companies make in order to grow their product line and gain profits are one of the drivers for the growth of the digital therapeutic (DTx) market. The privacy concerns related to digital therapeutic (DTx) apps may act as a restraint for the growth of the digital therapeutic (DTx) market. The collaboration between the companies will help in the growth of the market and will act as an opportunity for the digital therapeutic (DTx) market. The quality of digital therapeutic (DTx) is to be maintained in order to provide better treatment and proper care for the customers, hence, this needs to be done correctly, therefore this would act as challenge for the digital therapeutic (DTx) market because many a times the need is not met.   

The digital therapeutic (DTx) market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the digital therapeutic (DTx) market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Digital Therapeutic (DTx) Market Scope and Market Size

The digital therapeutic (DTx) market is categorized into four segments which are based on product and service type, application, purchase mode and sales channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of product and service type, the digital therapeutic (DTx) market is segmented into hardware products, solutions/software and service. In 2021, solutions/software segment is expected to dominate the market since there are number of smart phone users being increased.
• On the basis of application, the digital therapeutic (DTx) market is segmented into treatment/ care-related applications and preventive applications. In 2021, treatment/care-related applications segment is expected to dominate since it provides a good treatment and improve the life style of the people.   
• On the basis of purchase mode, the digital therapeutic (DTx) market is segmented into group purchase organization and individual. In 2021, individual segment is expected to dominate the market since many people individually are accepting the digital healthcare platform and preferring them in the pandemic situation.
• On the basis of sales channel, the digital therapeutic (DTx) market is segmented into B2B and B2C. In 2021, B2C segment is expected to dominate the market since the services are mostly preferred directly to the customers.

North America Digital Therapeutic (DTx) Market Country Level Analysis

North America digital therapeutic (DTx) market is analysed and market size information is provided by the country, product and service type, application, purchase mode and sales channel as referenced above.  

The countries covered in the North America digital therapeutic (DTx) market report are the U.S., Canada and Mexico.  

North America region holds the majority of the share in the digital therapeutic (DTx) market and is expected to witness the CAGR during the forecast period due to increasing number of cases in diabetes. The U.S. has the highest household spending in the world and offers trade agreements with several countries making it the largest market for consumer products including digital therapeutic (DTx) products

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

Strategic Initiatives by Manufacturers is creating new opportunities for Players in the Digital Therapeutic (DTx) Market

The digital therapeutic (DTx) market also provides you with detailed market analysis for every country growth in digital therapeutic (DTx) product sales, impact of advancement in the digital therapeutic (DTx) and changes in regulatory scenarios with their support for the digital therapeutic (DTx) market. The data is available for historic period 2011 to 2019.

Competitive Landscape and Digital Therapeutic (DTx) Market Share Analysis

The digital therapeutic (DTx) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to digital therapeutic (DTx) market.

The major players covered in the North America digital therapeutic (DTx) market report are Fitbit, Inc., Livongo, ResMed, Omada Health, Inc., Noom, Inc., Happify, Inc., Welldoc, Inc., SAMSUNG, ATENTIV, MANGO HEALTH, CogniFit, Kaia Health, Mindstrong Health, Smartpatient gmbh, Ayogo Health Inc., Ginger, Better Therapeutics, Inc., 2Morrow Inc., CANARY HEALTH, Click Therapeutics, Inc., Cognoa, Pear Therapeutics, Inc., Voluntis, Akili Interactive Labs, Inc. among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the digital therapeutic (DTx) market.

For instance,

• In August 2019, ATENTIV had agreed with Children’s Specialized Hospital’s Center. The collaboration tie-up between the two comprises of co-development of a unified behavioral and basic treatment operating system that utilizes the best clinical practices for the conveyance of ATENTIV mynd by primary care clinicians. This collaboration tie-up would increase the company’s brand value and market value of the product.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market players is enhancing the company market in the digital therapeutic (DTx) market which also provides the benefit for organization to improve their offering for digital therapeutic (DTx).   

SKU-59883